Drug Shortage Report for OMNIPAQUE 180
Report ID | 178377 |
Drug Identification Number | 02172720 |
Brand name | OMNIPAQUE 180 |
Common or Proper name | iohexol injection USP |
Company Name | GE HEALTHCARE CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | IOHEXOL |
Strength(s) | 388MG |
Dosage form(s) | SOLUTION |
Route of administration | SUBARACHNOIDAL SUBARACHNOIDAL |
Packaging size | 20 mL |
ATC code | V08AB |
ATC description | X-RAY CONTRAST MEDIA, IODINATED |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-12-13 |
Estimated end date | 2023-01-20 |
Actual end date | 2023-01-19 |
Shortage status | Resolved |
Updated date | 2023-01-20 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 1919 MINNESOTA COURT MISSISSAUGA, ONTARIO CANADA L5N 0C9 |
Company contact information | 800-387-7146 canadainfo@gehealthcare.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2023-01-20 | English | Compare |
v5 | 2023-01-19 | French | Compare |
v4 | 2023-01-19 | English | Compare |
v3 | 2022-12-14 | French | Compare |
v2 | 2022-12-14 | English | Compare |
v1 | 2022-12-14 | English | Compare |
Showing 1 to 6 of 6